UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000008583
Receipt number R000010082
Scientific Title Clinical research of safety and efficacy after a stop of dasatinib administration in patients with chronic myeloid leukemia -chronic phase (CML-CP) achieving a complete molecular response (CMR) on a treatment of tyrosine kinase inhibitors (TKIs).
Date of disclosure of the study information 2012/08/01
Last modified on 2020/08/06 09:31:22

No. Disposal Last modified on Item of update
1 Insert 2012/07/31 19:01:15
2 Update 2012/10/17 14:13:00 Email
Email1
3 Update 2012/10/29 15:55:15 Recruitment status
4 Update 2013/01/31 10:02:44 Institutions
5 Update 2013/08/05 11:56:29 Institutions
6 Update 2014/03/04 10:22:31 Key secondary outcomes
7 Update 2014/03/04 10:36:17 Email
Address
Address
Email
Institutions
8 Update 2014/08/04 08:40:41 Recruitment status
9 Update 2016/12/14 16:10:45 Key inclusion criteria
10 Update 2016/12/14 16:11:19 Name of primary person or sponsor
Organization
11 Update 2020/08/06 09:24:18 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
12 Update 2020/08/06 09:25:01 Number of participants that the trial has enrolled
13 Update 2020/08/06 09:31:22 Date of IRB
Last follow-up date